Tuesday, 9 March 2021 14.00 - 15.30 h
Combination products in the US are separately regulated by the FDA. For this reason, there is also an independent Office of Combination Products (OCP) whose task it is, among other things, to act as an "intermediary" between the other "offices". These offices are the Center for Devices and Radiological Health (CDRH, responsible for medical devices), the Center for Biologic Evaluation and Research (CBER, responsible for certain biotechnological products) and the Center for Drug Evaluation and Research (CDER, responsible for classical medicines and some biotechnological products).
A separate website for combination products is available, which is very clearly structured. It contains the following subpages:
The latter section "Guidance and Regulatory Information" is particularly interesting. In addition to legislation (e.g. cGMP rules on combination products), rules and regulations, you can also find "Guidance Documents" that provide further assistance. The 19 Guidance Documents are divided into "Pre-Market", "Post-Market" and Jurisdictional and are continuously supplemented or updated, e.g. when a draft document is finalised.
You can find these guidelines on the specific combination products guidance documents site.